国际妇产科学杂志

国际妇产科学杂志 ›› 2020, Vol. 47 ›› Issue (2): 152-154.

• 论著 • 上一篇    下一篇

阿帕替尼治疗耐铂型卵巢癌短期疗效与安全性观察

张锦，史惠蓉   

  1. 450052 郑州大学第一附属医院妇科
  • 收稿日期:2019-12-02 修回日期:2020-02-09 出版日期:2020-04-15 发布日期:2020-04-15
  • 通讯作者: 史惠蓉，E-mail：shuirong0089@126.com E-mail:shuirong0089@126.com
  • 基金资助:
     

Short-Term Efficacy and Safety of Apatinib in the Treatment of Platinum-Resistant Ovarian Cancer

ZHANG Jin，SHI Hui-rong   

  1. Department of Gynecology，The First Affiliated Hospital of Zhengzhou University，Zhengzhou 450052，China
  • Received:2019-12-02 Revised:2020-02-09 Published:2020-04-15 Online:2020-04-15
  • Contact: SHI Hui-rong，E-mail：shuirong0089@126.com E-mail:shuirong0089@126.com
  • Supported by:
     

PDF (PC)

7970

摘要： 目的：探讨阿帕替尼治疗耐铂型卵巢癌的短期疗效与安全性。方法：收集2015年7月—2019年1月在郑州大学第一附属医院治疗的耐铂型卵巢癌患者，根据治疗方案分为2组：单纯化疗组（吉西他滨+奥沙利铂）和阿帕替尼联合化疗组（阿帕替尼+吉西他滨+奥沙利铂）。评价2组患者的客观缓解率（ORR）和疾病控制率（DCR），并比较2组的不良反应发生率。结果：阿帕替尼联合化疗组的ORR（52.4% vs. 24.0%）及DCR（61.9% vs. 32.0%）均优于单纯化疗组，且治疗后CA125水平明显低于单纯化疗组，差异均有统计学意义（P＜0.05）。阿帕替尼联合化疗组的高血压、手足皮肤反应发生率较单纯化疗组高（P＜0.05），所有不良反应对症支持治疗后均可缓解。结论：阿帕替尼联合化疗治疗耐铂型卵巢癌安全有效。

关键词: 卵巢肿瘤；, 抗药性, 肿瘤；, CA-125抗原；, 治疗结果；, 安全；, 阿帕替尼

Abstract: Objective：To explore the short-term efficacy and safety of apatinib in the treatment of platinum-resistant ovarian cancer. Methods：Patients with platinum-resistant ovarian cancer treated at the First Affiliated Hospital of Zhengzhou University from July 2015 to January 2019 were collected and divided into 2 groups according to the treatment protocol: simple chemotherapy group (gemcitabine+oxaliplatin) and apatinib combined chemotherapy group (apatinib+gemcitabine+oxaliplatin). The objective remission rate (ORR) and disease control rate (DCR) were evaluated and the incidence of adverse reactions was compared in the 2 groups. Results：The ORR (52.4% vs. 24.0%) and DCR (61.9% vs. 32.0%) in the apatinib combined chemotherapy group were better than those in the simple chemotherapy group, and the level of CA125 after treatment was significantly lower than that in the simple chemotherapy group (P＜0.05). The incidence of hypertension and skin reaction of hand and foot in the apatinib combined chemotherapy group was higher than that in the simple chemotherapy group (P＜0.05), and all adverse reactions could be alleviated after symptomatic support treatment. Conclusions：Apaintib combined with chemotherapy is effective and safe in treating platinum-resistant ovarian cancer.

Key words: Ovarian neoplasms, Drug resistance, neoplasm, CA-125 antigen;, Treatment outcome;, Safety;, Apatinib

中图分类号: